There you go with your conspiracy theories,QuestionDoes ivermectin, with a maximum targeted dose of 600 μg/kg daily for 6 days, compared with placebo, shorten symptom duration among adult (≥30 years) outpatients with symptomatic mild to moderate COVID-19?
FindingsIn this double-blind, randomized, placebo-controlled platform trial including 1432 US adults with COVID-19 during February 2022 to July 2022, the median time to sustained recovery was 11 days in the ivermectin group and 12 days in the placebo group. In this largely vaccinated (83%) population, the posterior probability that ivermectin reduced symptom duration by more than 1 day was less than 0.1%.
MeaningThese findings do not support the use of ivermectin among outpatients with COVID-19.
